TQ-Ox, a novel synthetic derivative of thymoquinone on ovarian cancer cells in vitro


Kale E., Kale A., Bozali K., Gulgec A. S., ÖZDEMİR M., YALÇIN B., ...More

Natural Product Research, vol.37, no.18, pp.3015-3024, 2023 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 37 Issue: 18
  • Publication Date: 2023
  • Doi Number: 10.1080/14786419.2022.2144298
  • Journal Name: Natural Product Research
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Aquatic Science & Fisheries Abstracts (ASFA), Biotechnology Research Abstracts, CAB Abstracts, Chemical Abstracts Core, CINAHL, EMBASE, Food Science & Technology Abstracts, MEDLINE, Veterinary Science Database
  • Page Numbers: pp.3015-3024
  • Keywords: Apoptosis, genotoxicity, ovarian cancer, thymoquinone-oxime, APOPTOSIS, CISPLATIN
  • Marmara University Affiliated: Yes

Abstract

© 2022 Informa UK Limited, trading as Taylor & Francis Group.There are many studies in the literature on thymoquinone (TQ)-related cancer cells and models, and there is no relevant study investigating the efficacy of the oxime derivative of TQ (TQ-Ox). This study synthesized TQ-Ox and examined its cytotoxic, genotoxic and apoptotic properties in ovarian cancer cells. The structure TQ-Ox was confirmed with NMR. The cytotoxicity by luminometric ATP, intracellular reactive oxygen species (iROS) by fluorometric, intracellular calcium (iCa2+) by fluorometric, mitochondrial membrane potential (MMP) by flow cytometry, glutathione (GSH) levels with GSH/GSSG-Glo assay, DNA damage by comet assay, and apoptosis by acridine orange/ethidium bromide dye were determined. Concentrations of TQ-Ox were statistically increased cytotoxicity, DNA damage, apoptosis, iROS, and iCa2+ in a concentration-dependent manner (p < 0.001). Besides, MMP and GSH levels also decreased statistically significantly (p < 0.001) with increasing concentrations. TQ-Ox would be an effective treatment option by increasing cytotoxicity, genotoxicity, and apoptosis in ovarian carcinoma.